Mercado mundial del síndrome de hipersensibilidad a la tos: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado                              

El reflejo de la tos es un mecanismo de protección importante contra la aspiración, pero puede volverse hipersensible si se maneja mal. La tos crónica , en realidad, es una afección médica grave con una alta tasa de morbilidad. El síndrome de hipersensibilidad a la tos ha recibido ahora un paradigma unificado. Es una entidad clínica en la que la tos crónica es el síntoma principal, independientemente de la enfermedad subyacente. Aunque todavía es una teoría, nuevas investigaciones revelan que la neurofisiología anormal es la causa más común de esta enfermedad. Nuestra comprensión de los mecanismos de la tos ha evolucionado a la par de este cambio de paradigma en las últimas décadas, lo que nos permite dar aún más pasos adelante en el futuro.

Data Bridge Market Research analiza que el mercado del síndrome de hipersensibilidad a la tos se valoró en USD 8.31 mil millones en 2021 y se espera que alcance los USD 13.15 mil millones para 2029, registrando una CAGR del 5,90% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

La tos es la enfermedad más común en todo el mundo, según la OMS. El algoritmo de tratamiento está dejando de lado los compuestos pequeños y se está dirigiendo hacia los tratamientos biológicos y naturales. La terapia combinada se ha vuelto cada vez más común en los últimos años. Se están realizando ensayos clínicos para la mayoría de los productos patrocinados por la industria. El síndrome de hipersensibilidad a la tos tiene un impacto severo en la vida de los pacientes, incluyendo alteración del sueño, vómitos, mareos e incluso fracturas de costillas. Las infecciones, la enfermedad por reflujo gastroesofágico (ERGE), el asma y otros factores pueden contribuir a su aparición. Las empresas del mercado de tratamiento del síndrome de hipersensibilidad a la tos están impulsando la disponibilidad de babapentina y pregabalina, que son sustancias químicas relacionadas con el GABA que funcionan como neuromoduladores para el tratamiento del dolor neuropático y la epilepsia , porque la tos crónica produce un mayor malestar corporal. Se ha informado de que la gabapentina es bien tolerada en ensayos controlados con placebo para el tratamiento de la tos persistente refractaria.

Dinámica del mercado del síndrome de hipersensibilidad a la tos

Conductores

• Aumento de la prevalencia de enfermedades respiratorias crónicas

Se prevé que la creciente prevalencia de enfermedades respiratorias crónicas impulse el crecimiento del mercado del síndrome de hipersensibilidad a la tos. La tos es una enfermedad frecuente que afecta a millones de personas en todo el mundo. A nivel mundial, la prevalencia de trastornos respiratorios crónicos está aumentando, lo que da como resultado un aumento de los problemas de tos crónica. Como resultado, la creciente carga de enfermedades ofrece un futuro brillante para el mercado global. Aunque algunas investigaciones sugieren que otros factores, como el asma , el tabaquismo, un ambiente cálido y húmedo y enfermedades virales o bacterianas, pueden aumentar la probabilidad de contraer tos.

• Aumentar la inversión en infraestructura sanitaria

Another significant factor influencing the growth rate of cough hypersensitivity syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Healthcare industries are investing in opiates and GABA (gamma-aminobutyric acid)-related substances to help people with cough hypersensitivity. To treat chronic intractable cough, opiates are excellent cough suppressants and have antitussive actions. Similarly, corporations are expanding their tramadol production capabilities, an opioid prescription with a chemical makeup comparable to codeine medicines.

Furthermore, surging geriatric population and sedentary lifestyle of people such as high addiction of smoking will result in the expansion of cough hypersensitivity syndrome market. Along with this, favourable reimbursement policies and rising number of government initiatives to spread awareness will enhance the growth rate of the market.

Opportunities

• Rising number of clinical trials

Over the forecast period, the cough hypersensitivity syndrome market is expected to develop due to an increase in the number of clinical trials for the treatment of cough hypersensitivity syndrome. This is anticipated to boost the new market opportunities. The recent success of a P2X3 receptor antagonist in randomized clinical trials is the first major advancement in cough treatments in 30 years; it finally gives a method for treating persistent cough as well as a useful tool for unravelling the mechanism underlying cough hypersensitivity.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the cough hypersensitivity syndrome market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the cough hypersensitivity syndrome market. Additionally, lack of awareness among people and inefficiency of drugs along with its adverse effects will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cough hypersensitivity syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cough hypersensitivity syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cough hypersensitivity syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cough Hypersensitivity Syndrome Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The cough hypersensitivity syndrome market was hampered by the supply chain slowness. On the bright side, the cough hypersensitivity syndrome market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Global Cough Hypersensitivity Syndrome Market Scope

The cough hypersensitivity syndrome market is segmented on the basis of drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Inhales Corticosteroids
• Antitussive Agents
• Short-acting Beta-2 Agonists
• Anticholinergics
• Proton Pump Inhibitors
• Antihistamines
• Others

Route of Administration

• Oral
• Inhalation
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cough Hypersensitivity Syndrome Market Regional Analysis/Insights

The cough hypersensitivity syndrome market is analyzed and market size insights and trends are provided by country, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cough hypersensitivity syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the cough hypersensitivity syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of respiratory disorders and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging number of population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Análisis del panorama competitivo y de la cuota de mercado del síndrome de hipersensibilidad a la tos

El panorama competitivo del mercado del síndrome de hipersensibilidad a la tos proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la variedad del producto, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado del síndrome de hipersensibilidad a la tos.

Algunos de los principales actores que operan en el mercado del síndrome de hipersensibilidad a la tos son:

• Akorn, Incorporated (Estados Unidos)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Boehringer Ingelheim International GmbH (Alemania)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (Estados Unidos)
• Bayer AG (Alemania)
• Merck & Co., Inc. (Estados Unidos)
• Prestige Consumer Healthcare Inc. (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Almirall, SA (España)
• Zenomed Healthcare Private Limited (India)
• Productos farmacéuticos Cadila (India)

SKU-53276